IRIS

虹膜

• 批准号: 7378689
• 负责人: ANNAPURNI JAYAM TROUTH
• 金额: $ 0.44万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-15 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378689
• 关键词: aging; insulin sensitivity /resistance; myocardial infarction; placebos; stroke

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine if pioglitazone, currently approved for the treatment of type ii diabetes by reducing resistance, will reduce the overall risk for stroke and myocardial infarction in non-diabetic patients. Patients over the age of 44 years, who have had a recent ischemic stroke, will be enrolled if they have insulin resistance as tested per protocol. Patients who qualify will be on a doulbe blind study getting either placebo or pioglitazone for a total period of three years on the drug

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究将确定吡格列酮，目前批准用于治疗ii型糖尿病，通过减少阻力，将减少非糖尿病患者中风和心肌梗死的总体风险。年龄超过44岁且近期发生过缺血性卒中的患者，如果根据方案检测存在胰岛素抵抗，则将入组。符合条件的患者将接受为期三年的安慰剂或吡格列酮双盲研究